TO START A CELL LICENSING REQUEST – PLEASE FILL OUT REQUEST FORM

Next generation bioanalytical solutions

Our licensing process:

Fill out request form

Receive, review, and sign NDA

Review term sheet for license

Discuss details of license, finalize, sign and pay fees

Obtain cells under license

Receive Technical Support & Research Services

Neukopanel® Cell Request Form

for Proprietary Neukoplast® NK-92 Cells

Please complete form to initiate licensing process

Fill out my online form.
aNK

Innate Binding

aNK cells surveil each cell they encounter and are naturally equipped to recognize and bind to stress ligands expressed on cancer and virally infected cell surfaces via an array of innate receptors.

Activation

Upon engagement, aNK cells undergo cytolytic granule polarization towards the cell synapse in preparation for mass fusion with the membrane.

Degranulation

Cytolytic granules discharge their perforin, granzyme and cytokine contents into the synapse for direct exposure to the targeted cells.

Killing

The targeted cells are killed when holes are punched into the cellular and nuclear membranes and upon DNA degradation, chromatin condensation, mitochondrial depolarization and reactive oxygen species (ROS) formation.

haNK

Antibody Binding

Monoclonal antibodies bind to unique surface proteins on target cells, which in turn bind to CD16 receptors on haNK cells

Activation

Upon engagement, haNK cells undergo polarization and migration of cytolytic granules towards the cell synapse in preparation for mass fusion with the membrane.

Degranulation

Cytolytic granules discharge their perforin, granzyme and cytokine contents into the synapse for direct exposure to the targeted cells.

Eradication

Destructive enzymes break down the cell membrane and internal machinery, including the nucleus with its genetic code. The cancer cell then swells and ruptures, leaving only debris behind.

taNK

Epitope Binding

taNK® cells bind directly to unique surface proteins on targeted cells via their CAR receptors.

Activation

Once bound, the transmembrane portion of these CAR receptors relay activation signals to the cytoplasm, initiating a cascade of events leading to the migration and polarization of cytolytic granules towards the cell synapse.

Degranulation

These granules fuse with the membrane surface and discharge their perforin, granzyme and cytokines into synapse for direct exposure to the targeted cells.

Killing

Perforins punch holes in the cellular and nuclear membranes, allowing granzymes to enter and degrade the target cells from the inside. Destructive enzymes break down membrane structures and the internal machinery, including the nucleus with its genetic code. The targeted cells swell and rupture, leaving only debris behind.

aNK™, haNK®, and taNK® Informational and Technical Support Research Service

Killing Targeted cells are killed when destructive enzymes break down the cell membrane and internal machinery, including the nucleus with its genetic code. The cancer cell then swells and ruptures, leaving only debris behind.

aNK

direct killing using NK-92 derived activated NK cells (aNK) that release toxic granules directly into the cancer cells through cell-to-cell contact.

haNK

Antibody-mediated killing using haNKs, which are NK cells engineered to incorporate a high binding affinity receptor that binds to an administered antibody, designed to enhance the cancer cell killing effect of that antibody.

taNK

Chimeric Antigen Receptor directed killing using taNKs, which are NK cells engineered to incorporate chimeric antigen receptors (CARs) to target tumor-specific antigens found on the surface of cancer cells.

Taking you beyond the Brink of binding®
with our Killer Assays™.

THE NK-92® ASSAY COMPANY

Brink Biologics, Inc. (BBI) is a ImmunityBio, Inc. (NASDAQ: IBRX) affiliated biotechnology solutions company located in the prestigious Torrey Pines biotechnology science park in San Diego, CA.

KILLER CELLS - KILLER ASSAYS™

Natural Killer cell lines originating from a singular source, established in stable cultures under GLP & cGMP conditions and further modified into multiple panels of lines suitable for a range of laboratory testing applications.

Proprietary NEUKOPANEL® CELL LINES

A standardized panel of CD16 expressing NK-92® cell lines, provides for the first time the means to establish a consistent, robust and reliable assay for assessment of ADCC activity.

ADCC ASSAYS – ROUTINE HASSLE

Brink Biologics, Inc. holds the exclusive non-clinical rights to the NK-92 cell line and its CD16 expressing derivatives, all of which are uniquely and ideally suited for antibody-dependent cell-mediated cytotoxicity (ADCC) assays.

ROUTINE ASSAY
TIME CONSUMING AND A LACK OF OPTIONS

OUR SIMPLE SOLUTION

The exclusive global provider of THE NK-92 cell line (AND ITS VARIANTS) AND THE NEUKOPANELtesting services, NEUKOPANEL CELL PANELS, and sublicenses within the life sciences and device industry.

Highly published cell lines – over 200 publications.
Relevant Examples:
Schnueriger, A., et al. (2011). “Development of a quantitative, cell-line based assay to measure ADCC activity mediated by therapeutic antibodies.” Mol Immunol 48(12-13): 1512-1517.

Binyamin, L., et al. (2008). “Blocking NK cell inhibitory self-recognition promotes antibody-dependent cellular cytotoxicity in a model of anti-lymphoma therapy.” J Immunol 180(9): 6392-6401.

NK-92 cells are the only continuously growing human NK cell adapted to mass production
Brink Biologics created the NK-92 master cell bank (MCB).

EXCLUSIVE

NK-92 MCB has been accepted as clinical grade material by regulatory agencies across the world, including the US FDA, EMEA and Canada Health.
RECOGNIZED QUALITY

The sole holder of homogeneously pure NK-92 cell cultures with superb retention of phenotypic characteristics in more than 6 months of continuous culture.
PURE CELL LINE

Five Advantages of Neukopanel Cell Lines:

For the first time the means to establish a consistent, robust and reliable assay for assessment of true ADCC function.

Cost & Time Savings

True Cytotoxicity

Ease of Use

Robust Assay

Eliminates Phenotypic Variability

  • Cost and time savings over common practice using donor-sourced (PBMC) NK cell isolation, expansion and maintenance in short term cultures
  • Eliminates phenotypic variability of donor-sourced NK cells as Neukopanel cell lines offer clonal consistency, purity and reliability as an assay reagent
  • Ease of use over donor-sourced NK cells and capable of long-term continuous cultures
  • Ability to generate a readout spectrum with the use of our homozygous high and low affinity CD16 expressing lines alongside our negative control line for assay robustness
  • True cytotoxicity rather than cell-binding readouts

RECENT NEWS

Office

3530 John Hopkins Court
San Diego, CA 92121

Hours

8am to 5pm M-F

Call Us

Main: (858) 633-0300
Fax: (858) 380-1999

Email: info@brinkbiologics.com

©2015-2025 Brink Biologics, Inc. All Rights Reserved | Home | Privacy Policy | Legal Notice | Patent Notice

‘Brink Biologics’, ‘Taking You Beyond the Brink of Binding’, ‘Neukopanel’, ‘Killer Assays’ and ‘laNK’ are trademarks or registered trademarks of Brink Biologics, Inc., ‘haNK’, 'Neukoplast', and ‘NK-92’ are registered trademarks of ImmunityBio, Inc.
The content of this website is protected by Title 17 of the U.S. Code and may not be reproduced in whole or in part by any means.